A Queen's University study of two eye drugs used to treat wet Age-related Macular Degeneration (AMD) has determined the cheaper of the two could lead to eye inflammation, a potentially blinding adverse effect.
"This is a very important finding," says Sanjay Sharma (Ophthalmology and Epidemiology), a noted AMD and health policy researcher who also practices at Hotel Dieu Hospital. "It is particularly important because many seniors need numerous injections so the risk is cumulative."